Trius Therapeutics Inc (NASDAQ:TSRX)
During the Trading Day
| 7.95 |  +0.05 / +0.63% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 7.95 | +0.0016 / +0.02% |
Volume: 1.6K |
Latest TSRX News | Press Releases
| Cubist, Optimer, Trius: Antibiotic Deal Making On Tap May 22 / TheStreet.com |
Today’s Trading
| Previous close | 7.90 |
| Today’s open | 7.97 |
| Day’s range | 7.81 - 8.05 |
| Volume | 778,152 |
| Average volume (3 months) | 876,435 |
| Market cap | $378.2M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -105.80% |
| Earnings growth (this year) | +1.85% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | -33.71% |
| P/E ratio | NM |
| Price/Sales | 6.70 |
| Price/Book | 5.66 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SCMPSucampo Pharmaceutic... | +0.17 | +1.92% |
| SSRX3SBio Inc | +0.01 | +0.06% |
| LCILannett Company Inc | +0.09 | +0.71% |
| RPTPRaptor Pharmaceutica... | +0.11 | +1.68% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Next reporting date | August 15, 2013 |
| EPS forecast (this quarter) | -$0.32 |
| Annual revenue (last year) | $27.2M |
| Annual profit (last year) | -$53.9M |
| Net profit margin | -198.37% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Jeffrey L. Stein, PhD |
Chief Financial Officer & Secretary John P. Schmid, MBA |
Corporate headquarters San Diego, California |
Forecasts
